Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.57 |
| ▸ | MAOB | P27338 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | METAP2 | P50579 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30337692 | 0.89 | METAP2 (0.45) | KDM1AMAOBALDH1A1KDM4ENPC1 | |
| SCHEMBL8974216 | 0.89 | METAP2 (0.45) | KDM1AMAOBALDH1A1KDM4ENPC1 | |
| SCHEMBL30087143 | 0.87 | METAP2 (0.48) | KDM1AMAOBALDH1A1KDM4ENPC1 | |
| SCHEMBL6804411 | 0.87 | METAP2 (0.48) | KDM1AMAOBALDH1A1KDM4ENPC1 | |
| SCHEMBL3173634 | 0.79 | NPC1 (0.53) | KDM1AMAOBALDH1A1KDM4ENPC1 | |
| SCHEMBL18573201 | 0.79 | NPC1 (0.49) | KDM1AMAOBALDH1A1KDM4ENPC1 | |
| SCHEMBL13192068 | 0.79 | KDM1A (0.57) | KDM1AALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30436719 | 0.79 | NPC1 (0.53) | KDM1AMAOBALDH1A1KDM4ENPC1 | |
| SCHEMBL9237008 | 0.79 | KDM1A (0.57) | KDM1AALDH1A1KDM4ENPC1RAB9A | |
| SCHEMBL15614080 | 0.79 | HSD17B10 (0.56) | ALDH1A1KDM4ENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9573887-B2 | Naphthalene derivative | DAITO CHEMIX CORPORATION (JP) | 2017-02-21 | — | — | US | disclosed |
| EP-2599771-B1 | NAPHTHALENE DERIVATIVE | DAITO CHEMIX CORP (JP) | 2016-09-14 | — | — | EP | disclosed |
| US-9206129-B2 | Agent for treatment of eye diseases | DAITO CHEMIX CORPORATION (JP) | 2015-12-08 | — | — | US | disclosed |
| EP-2623494-B1 | AGENT FOR TREATMENT OF EYE DISEASES | DAITO CHEMIX CORP (JP) | 2015-09-02 | — | — | EP | disclosed |
| US-20140148416-A1 | Agent for Treatment of Eye Diseases | KYOTO UNIVERSITY (JP) | 2014-05-29 | — | — | US | disclosed |
| EP-2623494-A1 | AGENT FOR TREATMENT OF EYE DISEASES | Daito Chemix Corporation (JP) | 2013-08-07 | — | — | EP | disclosed |
| US-20130184241-A1 | Naphthalene Derivative | KYOTO UNIVERSITY (JP) | 2013-07-18 | — | — | US | disclosed |
| EP-2599771-A1 | NAPHTHALENE DERIVATIVE | Daito Chemix Corporation (JP) | 2013-06-05 | — | — | EP | disclosed |
| WO-2005037839-A1 | NORCANTHARIDIN DERIVATIVE COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF, COMPOSITIONS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | ENTOMED (FR) | 2005-04-28 | — | — | WO | disclosed |
| US-4508722-A | 1-Benzoyl-3-(arylpyridyl)urea compounds | ELI LILLY AND COMPANY (US) | 1985-04-02 | — | — | US | disclosed |
| US-4405552-A | INSECTICIDES | ELI LILLY AND COMPANY (US) | 1983-09-20 | — | — | US | disclosed |
| EP-0060071-A1 | Improvements in or relating to 1-benzoyl-3-(arylpyridyl)urea compounds | ELI LILLY AND COMPANY (US) | 1982-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148416-A1 | Agent for Treatment of Eye Diseases | PDE6A, ALDH1A2, PDE6D | KDM1A 2973/4885MAOB 1909/4885ALDH1A1 695/4885 |
| US-20130184241-A1 | Naphthalene Derivative | VCP, NOC2L, VAT1 | KDM1A 1691/4885MAOB 2080/4885ALDH1A1 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.